Immatics (NASDAQ:IMTX) Shares Purchased by Forefront Analytics LLC

Forefront Analytics LLC grew its stake in shares of Immatics (NASDAQ:IMTX) by 42.3% during the fourth quarter, HoldingsChannel reports. The firm owned 15,911 shares of the company’s stock after buying an additional 4,731 shares during the period. Forefront Analytics LLC’s holdings in Immatics were worth $113,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Bank of America Corp DE raised its holdings in shares of Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after buying an additional 2,231 shares during the period. Virtus ETF Advisers LLC lifted its position in shares of Immatics by 34.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company’s stock worth $68,000 after purchasing an additional 2,479 shares in the last quarter. Guggenheim Capital LLC purchased a new position in shares of Immatics in the fourth quarter valued at $101,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Immatics by 24.6% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company’s stock valued at $163,000 after purchasing an additional 4,477 shares in the last quarter. Finally, Aristides Capital LLC acquired a new stake in Immatics during the 4th quarter valued at $205,000. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Immatics in a report on Tuesday, April 1st. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Immatics currently has an average rating of “Buy” and a consensus target price of $16.67.

Immatics Trading Down 2.3 %

Immatics stock opened at $4.24 on Friday. Immatics has a 52 week low of $3.30 and a 52 week high of $13.77. The stock has a market cap of $515.37 million, a P/E ratio of -6.42 and a beta of 0.87. The stock has a 50 day moving average of $4.48 and a 200-day moving average of $6.03.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings data on Thursday, March 27th. The company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.51. The firm had revenue of $15.67 million for the quarter, compared to the consensus estimate of $16.16 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. As a group, equities analysts predict that Immatics will post -0.72 earnings per share for the current fiscal year.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.